KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study.

Carolina Barnett-Tapia, Elena Cortés Vicente, Robert M Pascuzzi, Kimiaki Utsugisawa, Jos Bloemers, Fiona Grimson, Thaïs Tarancón, Vera Bril, MycarinG study investigators

J Neurol 272(12) 752

PMID41205003
PMCIDPMC12596324
DOI10.1007/s00415-025-13480-8
发表日期2025-11-08
入排依据:未发现恶性肿瘤人群证据。
已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other;另有 1 张未列出。
摘要

摘要

BACKGROUND: Generalized myasthenia gravis (gMG) is an autoimmune disease characterized by fluctuating muscle weakness. The MG Impairment Index (MGII) incorporates patients' perspectives (22 items) and physician evaluation (6 items) of impairment. We evaluated the effect of rozanolixizumab using the MGII in the randomized, double-blind, placebo-controlled, Phase 3 MycarinG study. METHODS: Adult patients with gMG were randomized 1:1:1 to once-weekly rozanolixizumab 7 mg/kg, 10 mg/kg or placebo for 6 weeks. MGII assessment was optional. Exploratory MGII analyses included change from baseline (CFB) to Day 43 in total score and ocular/generalized subscores; higher scores reflect greater impairment. Post hoc analyses included responder rates (≥ 5.5-point improvement) and achievement of patient-acceptable symptom state (PASS; ≤ 10 points, patient-reported items only). RESULTS: Overall, 200 patients received rozanolixizumab 7 mg/kg (n = 66), 10 mg/kg (n = 67) or placebo (n = 67). The MGII was completed by 144/200 (72.0%) patients. Mean CFB in MGII total score was greater in the rozanolixizumab groups versus placebo; mean CFB in ocular and generalized subscores was consistent with the total score. At Day 43, 57.1%, 83.3% and 40.4% of patients, respectively, were responders, and 30.8%, 39.2% and 7.7%, respectively, achieved MGII PASS. Responsiveness correlations between MGII total score CFB and MG-ADL anchor at Day 43 demonstrated a Spearman's correlation coefficient of 0.5991 (p < 0.0001). CONCLUSION: These findings further support efficacy analyses from MycarinG to highlight the benefit of rozanolixizumab in patients with gMG and demonstrate the utility of the MGII in evaluating patient-relevant symptoms following treatment. TRIAL REGISTRATION: NCT03971422 (registered May 29, 2019).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Mean (SD) CFB to Day 43 in MGII total score and ocular and generalized subscores with MID at the group level. Randomized set. N is the number of patients who were included in the CFB at Day 43 analysis. *MID in MGII total score is 8.1 points for groups [25]; the threshold was determined as − 11.5 points when the MID was measured from the placebo mean CFB of − 3.4. † Patients with MGII data at baseline: N = 53, N = 55, N = 54 and N = 109 in the placebo, RLZ 7 mg/kg, RLZ 10 mg/kg and RLZ total groups, respectively. Figure adapted with permission from Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomized, double-blind, placebo-controlled, adaptive Phase 3 study . Lancet Neurol. 2023; 22(5):383–394. https://doi.org/10.1016/s1474-4422(23)00077-7 . CFB Change from baseline, MGII Myasthenia Gravis Impairment Index, MID Minimal important difference, RLZ Rozanolixizumab, SD Standard deviation
非 KM Figure
Fig. 2Fig. 2 MGII response rates at Day 43. Randomized set. Responders were defined as patients who achieved the MID in MGII total score of 5.5 points for individuals [25]. Percentages are based on the number of patients with non-missing data at each visit in the randomized set. N is the number of patients in each group assessed at Day 43. MGII Myasthenia Gravis Impairment Index, MID Minimal important difference, RLZ , Rozanolixizumab
非 KM Figure
Fig. 3Fig. 3 CFB to Day 43 in MGII individual items, grouped by a problems with your eyes, b problems eating, c problems speaking and breathing, and d generalized symptoms. Randomized set. In patients with baseline item score ≥ 1. Baseline is the last available value prior to the first injection of study drug in the treatment period, or if missing, the screening value. *Examination item. CFB Change from baseline, MGII Myasthenia Gravis Impairment Index, RLZ Rozanolixizumab
非 KM Figure
Fig. 4Fig. 4 Shift from score of ≥ 1 at baseline to score of 0 at Day 43 in individual items, grouped by a problems with your eyes, b problems eating, c problems speaking and breathing, and d generalized symptoms. Randomized set. Baseline is the last available value prior to the first injection of study drug in the treatment period, or if missing, the screening value. *Examination item. MGII Myasthenia Gravis Impairment Index, RLZ rozanolixizumab
非 KM Figure
Fig. 5Fig. 5 Indirect PASS responder rates for a MGII, b MG-ADL, c QMG, and d MGC. Randomized set. MGII, MG-ADL, QMG and MGC PASS achievement were defined as having ≤ 10-point, ≤ 2-point, ≤ 7-point and ≤ 3-point total score during the treatment period, respectively. MGII PASS achievement was measured across the 22 patient-reported items only. N is the number of patients in each group assessed at Day 43. MG-ADL Myasthenia Gravis Activities of Daily Living, MGC Myasthenia Gravis Composite, MGII Myasthenia Gravis Impairment Index, PASS Patient-acceptable symptom state, QMG Quantitative Myasthenia Gravis, RLZ Rozanolixizumab
非 KM Figure
Fig. 6Fig. 6 Scatter plot of responsiveness correlations between CFB in MGII total score and CFB in MG-ADL anchor at Day 43. Complete case analysis including all patients in the randomized set with non-missing MGII and MG-ADL total scores at baseline and Day 43. The MG-ADL anchor was classified as − 2 if achieving MSE (MG-ADL score of 0–1), − 1 for a ≥ 2-point improvement without MSE, 0 for a change of ≤ 1, and + 1 for ≥ 2-point worsening. Correlation coefficient and p-value were based on Spearman’s correlation. CFB Change from baseline, MG-ADL Myasthenia Gravis Activities of Daily Living, MGII Myasthenia Gravis Impairment Index, MSE Minimal symptom expression
非 KM Figure